If you're talking about Elvanse in Europe, it's a combination of "manufacturing issues" and "increased demand". I'm pretty sure it's mostly manufacturing issues

If you're talking about Elvanse in Europe, it's a combination of "manufacturing issues" and "increased demand". I'm pretty sure it's mostly manufacturing issues, because although there was a bump in diagnoses due to WFH it wasn't a massive bump. Takeda (who manufacture Elvanse in Europe) are being very coy about what "manufacturing issues" means. Their latest estimate for a return to full production is Q2 2024, but it's slipped before. /r/adhduk is quite good at tracking updates around shortages.